Changes of cytokines in the aqueous humor following Avastin intravitreous injection

doi:10.3969/j.issn.2095-4344.2014.42.016

Abstract

Abstract:

BACKGROUND: Studies on the inhibitory mechanism of Avastin for proliferative diabetic retinopathy are mostly confined to the vascular endothelial growth factor, while connective tissue growth factor and angiogenesis inhibitor also play an important role in the disease.
OBJECTIVE: To evaluate the changes of cytokines in the aqueous undergoing Avastin intravitreous injection or not prior to pars plana vitrectormy in the treatment of proliferative diabetic retinopathy.
METHODS: Thirty patients with proliferative diabetic retinopathy (30 eyes) were selected and randomly divided into groups A, B and C, each group containing 10 patients. Group A was treated with single pars plana vitrectormy; and group B and group C had 0.05 mL/1.25 mg and 0.1 mL/1.25 mg Avastin via intravitreous injection at 7 days before pars plana vitrectormy, respectively. Aqueous humor samples were collected during pars plana vitrectormy. The levels of vascular endothelial growth factor, connective tissue growth factor and pigment epithelium-derived factor were assessed by using ELISA technique.
RESULTS AND CONCLUSION: The levels of connective tissue growth factor and pigment epithelium-derived factor in the aqueous humor of two Avastin injection groups were increased significantly compared to the group with single pars plana vitrectormy. However, the level of vascular endothelial growth factor was lower in the Avastin injection groups. In addition, there was no significant difference between two Avastin injection groups. These results reveal that intravitreous injection of Avastin assisted vitrectomy for proliferative diabetic retinopathy is more effective than single pars plana vitrectormy treatment. The underlying mechanisms may be that Avastin could inhibit the intraocular angiogenesis by not only reducing the secretion of some growth factors but also increasing the levels of anti-angiogenesis related cytokines.

中国组织工程研究杂志出版内容重点：组织构建；骨细胞；软骨细胞；细胞培养；成纤维细胞；血管内皮细胞；骨质疏松；组织工程

全文链接：

Key words: eye, retinal diseases, diabetic mellitus, aqueous humor, cytokines

CLC Number:

R318

Xiao Jin-an, Bai Qing-yu, Xie An-ming . Changes of cytokines in the aqueous humor following Avastin intravitreous injection[J]. Chinese Journal of Tissue Engineering Research, 2014, 18(42): 6805-6810.

Figures/Tables 2

References

[1] Moss SE,KIein R,Klein BE.The 14. year incidence of visual 10SS in adiabetic population.Ophthalmology.1998;105: 998-1003.
[2] Macugen Diabetic Retinopathy Study Group.Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals.Ophthalmology.2006;113: 23-28.
[3] Spaide RF,Fisher YL.Intravitreal bevacizumab(Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage.Retina.2006;26:275-278.
[4] Yang CM, Yeh PT, Yang CH,et al.Bevacizumab pretreatment and long-acting gas infusion on vitreous clear-up after diabetic vitrectomy. Am J Ophthalmol.2008; 146:211-217.
[5] Avery RL, Pearlman J, Pieramici DJ, et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy.Ophthalmology.2006;113:1695-1705.
[6] Joukov V, Kaipainen A,Jeltsch M,et al.Vascular endothelial growth factor VEGF-B and VEGF-C.Cell physiol.1997;173(9): 211-214.
[7] 计岩,赵敏.贝伐单抗辅助玻璃体切除术治疗增生性糖尿病视网膜病变疗效的系统评价[J].重庆医科大学学报, 2013,38(12): 1481.
[8] Schmidinger G,Maar N,Bolz M,et al.Repeated intravitreal bevacizumab (Avastin(R)) treatment of persistent new vessels in proliferative diabetic retinopathy after complete panretinal photocoagulation. ActaOphthalmol. 2011;89(1):76-81.
[9] Ｒizzo S, Genovesi－Ebert F, Di Bartolo E, et al. Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol.2008; 246(6):837-842.
[10] Oshima Y, Shima C, Wakabayashi T, et al. Microincision vitrectomy surgery and intravitreal bevacizumab as a surgical adjunct to treat diabetic traction retinal detachment. Ophthalmology.2009; 116(5):927-938.
[11] Sinapis CI, Routsias JG, Sinapis AI, et al. Pharmacokinetics of intravitreal bevacizumab(Avastino)in rabbits.Clin Ophthalmol. 2011;5:697-704.
[12] Ferrara N.VEGF and the quest for tumour angiogenesis factors.NatRev Cancer.2002;2:795-803.
[13] Ruckman J, Green LS, Beeson J,et al. 2'-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). Inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain.J Biol Chem.1998;273(32): 205562-20556.
[14] 李巧, 李志红,2型糖尿病患者房水中VEGF和IL-6 含量的检测[J].山东大学学报:医学版,2007,45(1):88.
[15] Chen E, Park CH. Use of intravitreal bevacizumab as a preoperative adjunct for tractional retinal detachment repair in severe proliferative diabetic retinopathy.Retina.2006; 26: 699-700.
[16] Risau W, Flamme I.Vasculogenesis.Annu Rev Cell Dev Biol. 1995;11:73-91.
[17] Cunningham ET Jr, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema.Ophthamlology.2005;112(10):1747-1757.
[18] 万博,刘煜.作用于VEGF信号通路的血管生成抑制剂[J].药学进展,2010,34(6):256-263.
[19] Matsuyama K, Ogata N, Matsuoka M, et al.Relationship between pigment epithelium-derived factor (PEDF) and renal function in patients with diabetic retinopathy. Molecular Vision. 2008;14:992-996.
[20] Marumo T,Noll T, Schini-Kerth VB, et al. Significance of nitric oxide and peroxynitrite in permeability changes of the retinal microvascular endothelial cell monolayer induced by vascular endothelial growth factor. J Vase Res.1999;36(6): 510-515.
[21] 卢海,张风.增殖性糖尿病视网膜病变服内组织纤溶酶原激活物及其抑制物的表达与VEGF表达的相关性研究[J].国际眼科杂志, 2007, 7(3): 692-694.
[22] Hewett PW, Murray JC. Coexpression of fit-4 and KDR in freshly isolated and cultured human endothelial cells.Biochem Biophys Res Comrnun. 1996;221(3):697-702.
[23] Spirin KS, Saghizadeh M, Lewin SL,et al. Basement membrane and growth fact or gene expression in normal and diabetic human retinas.Curr Eye Res.1999;18(6): 490-499.
[24] Kuiper EJ, de Smet MD, van Meurs JC, et al.Association of Connective Tissue Growth Factor With Fibrosis in Vitreoretinal Disorders in the Human Eye.Arch Ophthalmol. 2006;124:1457-1462.
[25] Hughes JM, Kuiper EJ, Klaassen I, et al.Advanced glycation end products cause increased CCN family and extracellular matrix gene expression in the diabetic rodent retina. Diabetologia. 2007; 50 (5):1089-1098.
[26] Van Geest RJ, Lesnik-Oberstein SY, Tan HS, et al. A shift in the balance of vascular endothelial growth factor and connective tissue growth factor by bevacizumab causes the angiofibrotic switch in proliferative diabetic retinopathy. Br J Ophthalmol.2012; 96(4):587-590.
[27] Abu El-Asrar AM, Van den Steen PE, Al-Amro SA, et al. Expression ofangiogenic and fibrogenic factors in proliferative vitreo retinal disorders. Int Ophthalmol. 2007;27(1):11-22..
[28] He S, Chen Y, Khankan R, et al. Connective tissue growth factor as a mediator of intraocular fibrosis. Invest Ophthalmol Vis Sci. 2008;49(9):4078-4088.
[29] Kuiper EJ, de Smet MD, van Meurs JC, et al. Association of connective tissue growth factor with fibrosis in vitreoretinal disorders in the human eye. Arch Ophthalmol.2006; 124(10): 1457-1462.
[30] Khankan R, Oliver N, He S,et al. Regulation of fibronectin-EDA through CTGF domain-specific interactions with TGFbeta2 and its receptor TGFbetaRII. Invest Ophthalmol VisSci.2011;52(8):5068-5078.
[31] Hinton DR, He S, Jin ML, et al. Novel growth factors involved in the pathogenesis of proliferative vitreoretinopathy. Eye (Lond). 2002;16(4):422-428.
[32] Hinton DR, Spee C, He S, et al. Accumulation of NH2-terminal fragment of connective tissue growth factor in the vitreous of patients with proliferative diabetic retinopathy. Diabetes Care. 2004;27(3):758-764.